Specialty Quantity Limit Imbruvica 2282-H P2022a - Specialty Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan

Specialty Pharmacy Clinical Policy Bulletins
Aetna Non-Medicare Prescription Drug Plan

Subject: Specialty Quantity Limit Imbruvica 2282-H P2022a

Drug

IMBRUVICA (ibrutinib)

Policy:

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Imbruvica (ibrutinib) 70 mg capsules	30 per 30 days	Mantle Cell Lymphoma and Marginal Zone Lymphoma: 560 mg orally once daily until disease progression or unacceptable toxicity Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia: 420 mg orally once daily until disease progression or unacceptable toxicity Chronic Graft versus Host Disease (cGVHD): For patients age 12 years and older with cGVHD the dosage is 420 mg orally once daily, and for patients 1 to less than 12 years of age with cGVHD the dosage is 240 mg/m2 orally once daily (up to a dose of 420 mg), until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity Dose reduction: 70 mg to 420 mg orally once daily
Imbruvica (ibrutinib) 140 mg capsules	90 per 30 days
Imbruvica (ibrutinib) 140 mg tablets	30 per 30 days
Imbruvica (ibrutinib) 280 mg tablets	30 per 30 days
Imbruvica (ibrutinib) 420 mg tablets	30 per 30 days
Imbruvica (ibrutinib) 560 mg tablets	30 per 30 days
Imbruvica (ibrutinib) 70 mg/mL oral suspension	216 mL (2 bottles) per 36 days

Place of Service:

Outpatient

The above policy is based on the following references:

1. Imbruvica [package insert]. South San Francisco, CA: Pharmacyclics LLC; August 2022.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

December 29, 2022

Additional Information

Clinical Policy Bulletin Notes

Company Information \| Site Map	Aetna.com Home \| Help \| Contact Us \| Search
Web Privacy Statement \| Legal Statement \| Privacy Notices \| Member Disclosure